Trikafta 100-50-75 MG/75MG PKT 14S
Ended Awarded Last action
- Contract number
- SPE2DR26FCZG0
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $19,332
Award facts
- Contract value 100% obligated
- $19,331.61 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $19,331.61 to DMS Pharmaceutical Group Inc. for Trikafta 100-50-75 mg/75 mg packets (14-count) on January 15, 2026, with a completion date of January 16, 2026. This firm fixed-price delivery order was issued without a set-aside designation, allowing DMS Pharmaceutical Group to compete on an unrestricted basis. DMS Pharmaceutical Group Inc. is a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, specializing in distributing branded and generic pharmaceuticals, biologics, vaccines, and medical consumables to federal agencies, particularly the Department of Defense.
This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, designated as contract SPE2DR. The underlying PPV-G GEN V program represents a $30.3 billion acquisition strategy designed to establish multiple regional prime vendor contractors supplying pharmaceutical products to support military healthcare facilities worldwide. The parent IDC, awarded on November 13, 2025, carries a $499,999,999 ceiling value and extends through December 31, 2036, with a 30-month base period followed by three optional 30-month periods. As a PPV-G GEN V prime vendor, DMS Pharmaceutical Group is positioned as a critical supplier fulfilling diverse pharmaceutical requirements for Department of Defense healthcare operations globally.
Quick answers
Who was awarded contract SPE2DR26FCZG0?
SPE2DR26FCZG0 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 15, 2026.
How much is contract SPE2DR26FCZG0 worth?
The government has obligated $19,332 on SPE2DR26FCZG0.
Is contract SPE2DR26FCZG0 an order under another contract?
Yes. SPE2DR26FCZG0 is a delivery order under SPE2DR25D9127, an indefinite delivery contract.
Was contract SPE2DR26FCZG0 competed?
The extent of competition for SPE2DR26FCZG0 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award